CASP9 and papillary serous cystadenocarcinoma: There was a statistically significant difference between serum caspase-9 levels in women with ovarian serous cystadenoma and papillary serous cystadenocarcinoma (p ˂ 0.001) and there were statistically significantly lower serum levels of the studied parameters in women with these tumors compared to serum levels in healthy women (p ˂ 0.001), as shown in Figure 7.